Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2006-05-02
2006-05-02
Scheiner, Laurie (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
Reexamination Certificate
active
07037644
ABSTRACT:
This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly non-nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.
REFERENCES:
patent: 5631128 (1997-05-01), Kozal et al.
patent: 5650268 (1997-07-01), Kozal et al.
Larder, B. A., 1992, “3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors”, Antimicrob. Agents Chemother. 36(12):2664-9 (abstract provided).
Sakar, G. and Sommer, S.S. (1990) “The Megaprimer” Method of Site-Directed MutagenesisBiotech,8(4):404-407 (Exhibit 1).
Balzarini,J, (1998) “A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures With the Nonnucleoside Reverse Trascriptase Inhibitor Thiocarboxanilide UC-781”AIDS,14(3):255-260 (Exhibit 2).
Balzarini J, et al. (1997) “Zidovudine-Resistant Human Presence Immunodeficiency Virus Type 1 Strains Subcultured in the of Both Lamivudine and Quinoxaline HBY 097 Retain Marked Sensitivity to HBY 097 but not to Lamivudine”J. of Infect Dis,176:1392-1397 (Exhibit 3).
De Clercq E, (1997) “Development of Resistance of Human the 4); Immunodeficiency Virus (HIV) to Anti-HIV Agents: How to Prevent Problem”Intnl of Antimicro Agnts,9:21-26 (Exhibit 4).
Pelemans H, et al. (1997) “Characteristics of the Pro225His Mutation in Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase That Appears Under Selective Pressure of Dose-Escalating Quinoxaline Treatment of HIV-1”J. Viro,71(11):8195-8203 (Exhibit 5).
Shi C and Mellors JW, (1997) “A Recombinant Retroviral System I For Rapid In Vivo Analysis of Human Immunodeficiency Virus Type Susceptibility to Reverse Transcriptase Inhibitors”Antimicro Agnts and Chemothrp,41(12):2781-2785 (Exhibit 6).
Strair RK, et al. (1993) “Recombinant Retroviral Systems For the Analysis of Drug Resistant HIV”Nucl Acds Res,21(20): 4836-4842 (Exhibit 7).
U.S. patent application Ser. No. 5,650,268, Kozal, Michael, J., and Merigan, Thomas, C. May 20, 1997.
U.S. patent application Ser. No. 5,631,128, Kozal, Michael, J., and Merigan, Thomas, C. (1997) May 20, 1997.
Arnold E., et al. (1995) “Structures of DNA and RNA Polymerases and Their Interactions with Nucleic Acid Substrates”,Curr Opin Struct Biol5:27-38.
Balzarini J., et al., (1992) “HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity Against HIV-1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase”,Virology192:246-253.
Cheeseman S.H., et al. (1995) “Phase I/II Evaluation of Nevirapine Alone and in Combination with Zidvudine for Infection with Human Immunodeficiency Virus”,J Acquir Immune Defic Syndr8:141-151.
D'Aquilla R.T. (1994) “Molecular Pathogenesis and Laboratory Monitoring”,Clin Lab Med14:393-423.
DeJong, M.D., et al. (1994) “Alternating Nevirapine and Infected Zidovudine Treatment of Human Immunodeficiency Virus Type 1-Persons Does Not Prolong Nevirapine Activity”,J Infect Dis169:1346-1350.
Dueweke, T.J., et al. (1993) “A Mutation in Reverse to Other Transcriptase of Bis (Heteroaryl) Piperzine Resistant Human Immunodeficiency Virus Type 1 That Confers Increased Sensitivity Nonnucleoside Inhibitors”,PNAS,90:4713-4717.
Eastman, P. Scott, et al. (1995) Monisotopic Hybridization Assay for Determination of Relative Amounts of Genotypic Human Micro, Immunodeficiency Virus Type 1 Zidovudine Resistance,J Clin Micro,2777-2780.
Frost, S.D.W., and McLean, A.R. (1994) “Quasispecies Dynamics and the Emergence of Drug Resistance During Zidovudine Therapy of HIV Infection”,AIDS,8:323-332.
Holodniy, Mark, et al. (1995) “Determination of Human Immunodeficiency Virus RNA In Plasma and Cellular Viral DNA Genotypic Zidovudine Resistance Combination Therapy”,J. Virol,3510-3516.
Kellam, P., et al. (1994) “Zidovudine Treatment Results in the Selection of Human Immunodeficiency Virus Type 1 Variants Whose Genotypes Confer Increasing Levels of Drug Resistance”,J Gen Virol75:341-351.
Lieven Stuyver, et al. (1997) “Line Probe Assay For Rapid Detection Of Drug Selected Mutations In The Human Immunodefiency Virus Type 1 Reverse Transcriptase Gene”,Antimicro Agen and Chemother,284-291.
Mohri, H., et al. (1993) “Quantitation of Zidovudine Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients”,PNAS90:25-29.
Nájera, I., et al. (1994) “Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates”,Aids Res Hum Retroviruses10:1479-1488.
Nájera, I., et al. (1995) “pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in virus from Patients Undergoing No Drug Therapy”,J. Virol69:23-31.
Nunberg, J.H., et al. (1990) “Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors”,J Virol65:4887-4892.
Richman, D.D. et al. (1994) “Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected during Therapy”,J Virol68:1660-1666.
Richman, D.D. et al. (1991) “Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase Arise in Tissue Culture”,PNAS88:11241-11245.
Sanger et al. (1977) “DNA Sequencing with Chain-terminating Inhibitors”,PNAS74:5463-5467.
Parkin Jeffrey S.
Pennie & Edmonds LLP
Scheiner Laurie
ViroLogic, Inc.
LandOfFree
Means and methods for monitoring non-nucleoside reverse... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Means and methods for monitoring non-nucleoside reverse..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means and methods for monitoring non-nucleoside reverse... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3559893